Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLCByKersti Oselin, MD, PhDJune 26th 2023Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.